LOS ANGELES, Aug. 4, 2011 /PRNewswire/ — NeuroSigma, Inc., a
Los Angeles-based medical device company, today provided an update
in response to substantial interest and inquiries generated by a
National Public Radio (NPR) news story which aired July 27, 2011 on
the use of non-invasive Trigeminal Nerve Stimulation (TNS) for the
treatment of drug-resistant epilepsy.
Dr. Christopher DeGiorgio, a neurologist at the University of
California, Los Angeles (UCLA) and scientific advisor to
NeuroSigma, who was interviewed in the NPR story, pioneered the
development of TNS for epilepsy. NeuroSigma is the exclusive
licensee of UCLA’s TNS intellectual property.
NeuroSigma is now planning a Phase III pivotal trial for its
external TNS (eTNS™) system. Earlier this year, Dr.
DeGiorgio delivered results of the 50-subject Phase II double-blind
clinical trial to the Antiepileptic Drug Trials XI Conference in
Miami, Florida. The results compared favorably with those of
pharmaceuticals and surgically-implanted devices. (
The study found that subjects receiving NeuroSigma’s active
eTNS™ treatment experienced a significant improvement in
seizure reduction, while those randomized to receive the control